RxDoctor Payments Data

Padmaja Annamaneni, MD

Psychiatry · Perth Amboy, NJNPI 1205914520

Payments from drug & device makers

$615in general payments, 2019–2025

Across 54 payments — averaging $11.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$180
  • AbbVie$167
  • Neurocrine Biosciences, Inc.$115
  • Otsuka America Pharmaceutical, Inc.$47
  • Indivior Inc.$32
  • Sunovion Pharmaceuticals Inc.$27
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$615100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$615 in reported general payments places this provider in the 65th percentile of 1,119 psychiatry providers in New Jersey.

See all psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$5,552
Medicare patients
21
Services billed
72

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate43$115,701
Abilify MaintenaAripiprazole12$35,625
FanaptIloperidone12$30,113
VraylarCariprazine Hcl13$16,884
Risperdal ConstaRisperidone Microspheres15$12,860
Paliperidone ErPaliperidone34$6,447
Aripiprazole140$6,315
Olanzapine OdtOlanzapine32$5,250
Divalproex Sodium ErDivalproex Sodium63$4,909
Chlorpromazine Hcl16$3,633
Bupropion XlBupropion Hcl124$3,119
Ziprasidone Hcl25$2,659
Clozapine29$2,269
Risperidone94$1,849
Quetiapine Fumarate111$1,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$180$128,56158 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$47$35,62512 claims
Vanda Pharmaceuticals Inc.Fanapt$14$30,11312 claims
AbbVieVraylar$167$16,88413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,119 psychiatry providers in New Jersey.

Other psychiatry in Perth Amboy

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →